Investment Thesis

• FuzeonTM (T-20) – First anti-HIV fusion inhibitor

  • New class – meets unmet medical need
  • NDA filed September 16th
  • Priority Review status with FDA
  • European application filed September 19th

• T-1249 – second generation

  • currently in Phase I/II

• Collaboration with Roche

  • Development, manufacturing & commercialization
  • 50/50 profit share in U.S., royalty ROW

• Pipeline to expand HIV fusion inhibitor franchise

  • Novel peptide research collaboration

Previous slide

Next slide

Back to first slide

View graphic version